The antihyperglycemic and hypolipidemic activities of a sulfur-oxidovanadium(IV) complex

This study describes the synthesis, characterization, and biological activity of a new class of antidiabetic oxidovanadium(IV)-complexes with S 2 O 2 coordination mode. The target complex 3,6-dithio-1,8-octanediolatooxidovanadium(IV), abbreviated as ([V IV O(octd)]), where octd = 3,6-dithio-1,8-octanediol, is formed from the reaction between the 3,6-dithio-1,8-octanediol and vanadyl sulfate (V IV OSO 4 ). The effects of treatment with ([V IV O(octd)] on blood glucose , lipidic profile, body weight , food intake, water intake, urinary volume, glycogen levels , and biomarkers for liver toxicity were investigated using a streptozotocin (STZ)-induced diabetic Wistar rats model. The results have shown that the [V IV O(octd)] complex caused a significant decrease in blood glucose (247.6 ± 19.3 mg/dL vs 430.1 ± 37.6 mg/dL diabetic group, p < 0.05), triglycerides (TG, 50%) and very low-density cholesterol (VLDL-C, 50%) levels in STZ-diabetic rats after 3 weeks of treatment. The [V IV O(octd)] has shown antihyperglycemic activity in diabetic rats as well as a reduction in elevated lipid levels . Time-dependent studies using EPR and 51 V NMR spectroscopy of [V IV O(octd)] were done in aqueous solutions to determine the complex stability and species present in the oral gavage solution used for complex administration. The spectroscopic studies have shown that the antidiabetic/hypolipidemic activity could be attributed to [V IV O(octd)], vanadium species resulting from redox processes , the hydrolysis of [V IV O(octd)] and its decomposition products, or some combination of these factors. In summary, the oxidovanadium(IV) complex containing the S 2 O 2 donor ligand has desirable antidiabetic properties eliminating the symptoms of Diabetes mellitus and its comorbidities.